Senescent cells in Giant Cell Arteritis have inflammatory phenotype participating in tissue injury via IL-6 dependent pathways
暂无分享,去创建一个
C. Kittas | D. Thanos | C. Salvarani | A. Polyzou | A. Cavazza | S. Croci | V. Gorgoulis | A. Tzioufas | E. Xingi | K. Boki | K. Kambas | F. Muratore | S. Havaki | C. Marvisi | K. Evangelou | D. Veroutis | AV Goules | OD Argyropoulou | DA Palamidas | E. Karatza | C. Ricordi | E. Galli
[1] E. Brouwer,et al. Indication of Activated Senescence Pathways in the Temporal Arteries of Patients With Giant Cell Arteritis , 2023, Arthritis & rheumatology.
[2] Soyoung Lee,et al. COVID-19 and cellular senescence , 2022, Nature Reviews Immunology.
[3] I. Wicks,et al. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2022, Annals of the Rheumatic Diseases.
[4] C. Dani,et al. Senescent macrophages in the human adipose tissue as a source of inflammaging , 2022, GeroScience.
[5] F. Buettner,et al. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. , 2022, Cancer cell.
[6] B. Stripp,et al. Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis , 2022, European Respiratory Journal.
[7] A. Aboussekhra,et al. Tocilizumab suppresses the pro-carcinogenic effects of breast cancer- associated fibroblasts through inhibition of the STAT3/AUF1 pathway. , 2021, Carcinogenesis.
[8] J. Stone,et al. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension , 2021, Rheumatology.
[9] Daniele Di Mauro,et al. New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine? , 2021, The Lancet. Rheumatology.
[10] A. Lazaris,et al. Neutrophil extracellular traps in giant cell arteritis biopsies: presentation, localization and co-expression with inflammatory cytokines. , 2021, Rheumatology.
[11] J. Campisi,et al. Algorithmic assessment of cellular senescence in experimental and clinical specimens , 2021, Nature Protocols.
[12] J. Gil,et al. Senescence and the SASP: many therapeutic avenues , 2020, Genes & development.
[13] C. Schmitt,et al. Cellular Senescence: Defining a Path Forward , 2019, Cell.
[14] V. Gorgoulis,et al. Senescence and senotherapeutics: a new field in cancer therapy , 2019, Pharmacology & therapeutics.
[15] L. Tian,et al. MMP (Matrix Metalloprotease)-9–Producing Monocytes Enable T Cells to Invade the Vessel Wall and Cause Vasculitis , 2018, Circulation research.
[16] C. Kallenberg,et al. Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis? , 2018, Arthritis & rheumatology.
[17] S. Melov,et al. Unmasking Transcriptional Heterogeneity in Senescent Cells , 2017, Current Biology.
[18] A. Rizzo,et al. New insights into the pathogenesis of giant cell arteritis. , 2017, Autoimmunity reviews.
[19] C. Wijmenga,et al. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. , 2017, American journal of human genetics.
[20] Sagar,et al. DNA Damage Signaling Instructs Polyploid Macrophage Fate in Granulomas , 2016, Cell.
[21] C. Conover,et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis , 2016, Science.
[22] N. Karamanos,et al. Ionizing radiation-mediated premature senescence and paracrine interactions with cancer cells enhance the expression of syndecan 1 in human breast stromal fibroblasts: the role of TGF-β , 2016, Aging.
[23] Ansar Karimian,et al. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. , 2016, DNA repair.
[24] L. Cimino,et al. MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis , 2015, Annals of the rheumatic diseases.
[25] C. Weyand,et al. Immune mechanisms in medium and large-vessel vasculitis , 2013, Nature Reviews Rheumatology.
[26] P. Barnes,et al. Dysfunction of Endothelial Progenitor Cells from Smokers and Chronic Obstructive Pulmonary Disease Patients Due to Increased DNA Damage and Senescence , 2013, Stem cells.
[27] C. Franceschi,et al. MicroRNAs linking inflamm-aging, cellular senescence and cancer , 2013, Ageing Research Reviews.
[28] A. Iagnocco,et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative , 2012, Annals of the rheumatic diseases.
[29] Y. J. Liao,et al. Giant cell arteritis: immune and vascular aging as disease risk factors , 2011, Arthritis research & therapy.
[30] J. Campisi,et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. , 2010, Annual review of pathology.
[31] Javier Martín,et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. , 2009, Arthritis and rheumatism.
[32] J. Nolla,et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. , 2007, Seminars in arthritis and rheumatism.
[33] C. Nordborg,et al. Early menopause, low body mass index, and smoking are independent risk factors for developing giant cell arteritis , 2005, Annals of the rheumatic diseases.
[34] D. Colomer,et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. , 2003, Rheumatology.
[35] A. Papavassiliou,et al. p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner. , 2003, The EMBO journal.
[36] G. Hannon,et al. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[37] D A Bloch,et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.